|
Page 5 of 5
REFERENCES
Arnsten AFT: Dopaminergic and noradrenergic influences on cognitive functions. In: Stimulant Drugs and ADHD: Basic and Clinical Neuroscience Edited by Solanto MV, Arnsten AFT, Castellanos FX New York, Oxford University Press, 2001, pp 185-208.
Barkley RA, Murphy KR, DuPaul GI, Bush T: Driving in young adults with attention deficit hyperactivity disorder: Knowledge, performances adverse outcomes, and the roleof executive functioning . J. Neuropsychol Soc 8: 655-672. 2002.
Biederman J, Spencer T: Attention- deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46:1234-1242, 1999.
Brown TE: Emerging understandings of attention deficit disorders and comorbidities. In: Attention Deficit Disorders and Comorbidities in Children, Adolescents and Adults. Edited by Brown TE. Washington (DC), American Psychiatric Press, 2000, pp 3-55.
Bymaster FP, Katner JS, Nelson DL, HemrickLuecke 5K, Threlkeld PC, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW: Atomoxetine increases extracellular levels of norepinephrine and doparnine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder Neuropsychopharmacology 27:699-711, 2002.
Gammon GD, Brown TE: Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharrnacol 3:1-10, 1993.
Gehlert DR. Gackenheimer SL, Robinson DW: Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci Lett157:203-206, 1993
Grace AA: Psychostimulant actions on dopamine and limnbic system function: Relevance to the pathophysiology and treatment of ADHD. In: Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. Edited by Solanto MV, Arnsten AFT, Castellanos FX. New York, Oxford University Press, 2001, pp 134-157.
Greenhill L: Stimulant medication treatment of children with attention deficit hyperactivity disorder. In: Attention Deficit Hyperactivity Disorder: State of the Science, Best Pracfices Edited by Jensen PS, Cooper JR. Kingston (New Jersey), Civic Research Institute, 2002, pp 1-27.
Greenhill L, Halperin JM, Abikoff H: Stimulant medications. J Am Acad Child Adolesc Psychiatry 38:503-512, 1999.
Lanau F, Zenner M, Civelli O, Hartmann D: Epinephrine and norepinephrine act as potent agonists at the recombinant human dopamine D4 receptor J Neurochem 68:804-812, 1997.
Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke I, DietrichA, Milton D: Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry 53:112-120, 2003.
Michelson D. Allen AJ, Busner J. Casat C, Dunn D, Kratochvil C, Newcom J, Sallee FR, Sangal RB, Saylor K, West SA, Kelsey D, Wernicke J, Trapp NJ, Harder D: Once-daily atomoxetine for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. AmJ Psychiatry 159:1896-1901,2002
Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T; Atomoxetine ADHD Study Group: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 108:E83, 2001
Pliszka SR: Comparing the effects of stimulant and non-stimulant agents on catecholamn~e function: Implications for theories of ADHD. In: Stimulant Drugs and ADHD: Basic and Clinical Neuxoscjence Edited by Solanto MV, Arnsten AFT, Castellanos FX. New York, Oxford University Press, 2001, pp 332-352.
Safer DJ, Zito JM, Doskeis 5: Concomitant psychotropic medication for youths. Am J Psychiatry 160:438-449,2003.
Solanto MV, Arnsten AFT, Castellanos FX: Neuroscience of stimulant drug action in ADHD. In; Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. Edited by Solanto MV ArnstenAFT, Castellanos FX. New York, Oxford University Press, 2001, pp 355-379.
Wong DT, Threlkeld It, Best KL, Bymaster FP: A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 222:61-65, 1982.
next: Natural Alternatives: Information
|
